|
|
 |
Dr. Brian G. Gazzard of the Chelsea and Westminster Hospital in London and colleagues report in the July issue of the
Journal of Neurology, Neurosurgery, and
Psychiatry that the administration of
zidovudine (AZT) before the onset of AIDS and continued after the development of the disease helps protect against HIV-related dementia and opportunistic brain infections.
The researchers examined the medical records of 1,109 AIDS patients between 1991 and 1994, looking for effects of zidovudine in relation to HIV-related dementia, progressive
multifocal leukoenchephalopathy, cerebral toxoplasmosis, and primary central nervous system lymphoma. Zidovudine treatment was associated with decreased risk of the disease, with a 14 percent to 32 percent decrease in the
incidence of the diseases for every six months of follow-up. None of the other drugs researched by the scientists showed protective value in the treatment of these disorders.
Editor's Note: from Reuters
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
